Lifeward Misses EPS Estimates by $0.66 as Revenue Falls Short

Lifeward (NASDAQ:LFWD) reported a quarterly loss of $1.44 per share on Friday, missing analysts' consensus estimate of a $0.78 loss by $0.66. Revenue came in at $5.43 million for the quarter, well below the $7.24 million analysts expected, according to FiscalAI.

The miss was steep on both lines. Profitability metrics underscore the pressure: the company posted a negative return on equity (ROE, net income as a share of shareholder equity) of 235.86% and a negative net margin (profit as a share of revenue) of 141.28%. In plain words, Lifeward lost more than it earned in revenue several times over after all expenses.

How did the market react?

Shares fell $1.66 on Friday, closing at $4.06. Trading volume spiked to 30,374 shares against an average of 14,890 — roughly double the norm, a sign investors repositioned quickly on the news.

The stock now sits near the bottom of its range. Lifeward's twelve-month low is $3.81 and its twelve-month high is $9.61. The 50-day moving average stands at $6.42 and the 200-day moving average at $6.87, so Friday's close sits well below both trend lines.

The balance sheet picture is mixed. The company carries a debt-to-equity ratio (total debt relative to shareholder equity) of 0.70, a quick ratio (liquid assets against short-term liabilities) of 1.77 and a current ratio of 2.33. Those liquidity readings look comfortable on paper, even as the income statement deteriorates.

The stock has a market cap of $11.49 million, a price-to-earnings ratio of -0.24 (negative because the company is unprofitable) and a beta of 0.55, meaning it historically moves less than the broad market.

What are analysts saying?

Several brokerages have weighed in recently:

• HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on Friday, August 21st.
• Citigroup reissued a "buy" rating on Friday, August 21st.
• Zacks Research raised Lifeward from "strong sell" to "hold" in a report on Monday, July 27th.
• Weiss Ratings upgraded the stock from "sell (e+)" to "sell (d-)" on Friday, October 9th — a bump, but still a sell.

In aggregate, two analysts rate the stock a Buy, one a Hold and one a Sell. MarketBeat data puts the average rating at "Hold" with a consensus price target of $10.00 — implying significant upside if the Street's target holds, though the spread in ratings signals sharp disagreement.

What does Lifeward actually do?

Lifeward Ltd. is a medical technology company developing and commercializing wearable robotic systems for people with mobility impairments. Its principal product is the ReWalk Personal Exoskeleton, a battery-powered wearable robotic device that lets individuals with lower-limb disabilities — including those from spinal cord injury — walk with crutches or other support.

The company was formerly known as ReWalk Robotics and adopted the Lifeward name in 2024.

For a $11.49 million-cap company burning cash with a 141.28% negative net margin, the path forward depends on revenue recovery, not rating upgrades. Friday's print showed the gap between promise and numbers is still wide.